ChiCTR2600118731 版本V1.0 版本创建时间2026/02/10 14:27:07 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600118731 

最近更新日期:

Date of Last Refreshed on:

2026-02-10 14:26:21 

注册时间:

Date of Registration:

2026-02-10 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

机器人辅助腹腔镜、开放手术在肾癌合并下腔静脉瘤栓切除的应用:一项前瞻性研究

Public title:

Application of Robot-Assisted Laparoscopic and Open Surgery in the Resection of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus:A prospective clinical trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

机器人辅助腹腔镜、开放手术在肾癌合并下腔静脉瘤栓切除的应用

Scientific title:

Application of Robot-Assisted Laparoscopic and Open Surgery in the Resection of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

姚林 

研究负责人:

姚林 

Applicant:

Lin Yao 

Study leader:

Lin Yao 

申请注册联系人电话:

Applicant telephone:

+86 159 9012 1150

研究负责人电话:

Study leader's telephone:

+86 159 9012 1150

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

zyydoctor2021@163.com

研究负责人电子邮件:

Study leader's E-mail:

zyydoctor2021@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市西城区西什库大街8号

研究负责人通讯地址:

北京市西城区西什库大街8号

Applicant address:

No.8 Xishiku Street, Xicheng District, Beijing, China

Study leader's address:

No.8 Xishiku Street, Xicheng District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京大学第一医院

Applicant's institution:

Peking University First Hospital

研究负责人所在单位:

北京大学第一医院

Affiliation of the Leader:

Peking University First Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2026R0046-0001

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

北京大学第一医院生物医学研究伦理委员会

Name of the ethic committee:

Ethics Committee for Biomedical Research, Peking University First Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2026-02-02 00:00:00

伦理委员会联系人:

胡艳

Contact Name of the ethic committee:

Hu Yan

伦理委员会联系地址:

北京市西城区西什库大街8号

Contact Address of the ethic committee:

No.8 Xishiku Street, Xicheng District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 6611 9025

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

北京大学第一医院

Primary sponsor:

Peking University First Hospital

研究实施负责(组长)单位地址:

北京市西城区西什库大街8号

Primary sponsor's address:

No. 8, Xishiku Street, Xicheng District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学第一医院

具体地址:

北京市西城区西什库大街8号

Institution
hospital:

Peking University First Hospital

Address:

No. 8, Xishiku Street, Xicheng District, Beijing, China

经费或物资来源:

Source(s) of funding:

None

Target disease:

Renal cell carcinoma

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

本研究旨在通过前瞻性队列研究,纳入接受机器人辅助腹腔镜、开放肾癌合并下腔静脉瘤栓切除术的患者,评估机器人辅助腹腔镜手术、开放手术在肾癌合并下腔静脉瘤栓切除中的效果差异,具体目标包括:机器人辅助腹腔镜手术、开放手术在手术时间、术中出血量等方面的差异,对比围手术期并发症、术后住院时长以及术后肿瘤进展情况的差异。  

Objectives of Study:

This study aims to enroll patients undergoing robot-assisted laparoscopic surgery or open surgery for renal cell carcinoma (RCC) complicated with inferior vena cava (IVC) tumor thrombus through a prospective cohort design, and evaluate the efficacy differences between these two surgical approaches in the resection of RCC with IVC tumor thrombus. The specific objectives include: comparing the differences in surgical duration, intraoperative blood loss, etc., between robot-assisted laparoscopic surgery and open surgery; and analyzing the variations in perioperative complications, postoperative hospital stay duration, and postoperative tumor progression.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①年满18周岁 ②在我院接受机器人辅助腹腔镜、开放手术方式切除肾癌合并下腔静脉瘤栓的患者。 ③无严重心脑血管疾病、肝肾功能不全、血液系统疾病以及其他严重临床合并症,非妊娠状态。 ④临床资料和实验室检查结果完整。 ⑤同意参加研究并签署无异议文件。 ⑥能够表示同意并理解研究目的。

Inclusion criteria

1. Aged 18 years or older; 2. Patients who undergo robot-assisted laparoscopic surgery or open surgery for resection of renal cell carcinoma (RCC) complicated with inferior vena cava (IVC) tumor thrombus at our hospital; 3. Free from severe cardiovascular/cerebrovascular diseases, hepatic/renal dysfunction, hematological disorders, and other serious clinical comorbidities, non-pregnant; 4.Complete clinical data and laboratory test results; 5. Agree to participate in the study and sign the informed consent document; 6. Capable of providing consent and understanding the purpose of the study.

排除标准:

①未满18周岁。 ②临床资料和实验室检查结果不完整。 ③妊娠状态或哺乳期妇女。 ④合并其他严重临床合并症等。 ⑤研究者认为不适合参加该研究。

Exclusion criteria:

1.Under 18 years of age; 2.Incomplete clinical data or laboratory test results; 3.Pregnant or lactating women; 4.Complicated with other serious clinical comorbidities; 5. Deemed ineligible for participation in the study by the investigator.

研究实施时间:

Study execute time:

From 2026-02-25 00:00:00 To 2028-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-02-25 00:00:00 To 2028-12-31 00:00:00  

干预措施:

Interventions:

组别:

机器人辅助腹腔镜手术组

样本量:

20

Group:

RAL-RN-IVCT group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

开放手术组

样本量:

20

Group:

Open-RN-IVCT group

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China 

Province:

Beijing 

City:

 

单位(医院):

北京大学第一医院 

单位级别:

三甲 

Institution
hospital:

Peking University First Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

手术信息

指标类型:

主要指标

Outcome:

Surgical parameters

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后转归情况

指标类型:

主要指标

Outcome:

Postoperative outcomes

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

影像学检查数据

指标类型:

次要指标

Outcome:

Imaging data

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

实验室检查数据

指标类型:

次要指标

Outcome:

Laboratory parameters

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

人口学信息

指标类型:

次要指标

Outcome:

Demographics

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

共病

指标类型:

次要指标

Outcome:

Comorbidities

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肿瘤学特征

指标类型:

次要指标

Outcome:

Oncological characteristics

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No sharing

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

使用病例记录表(Case Record Form, CRF)和电子采集管理系统(Electronic Data Capture, EDC)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Report Forms (CRF) and an Electronic Data Capture (EDC) system were utilized for data collection.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-02-10 14:26:21